HC Wainwright Has Optimistic Outlook of FULC FY2024 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Investment analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.12) per share for the year, up from their prior forecast of ($0.15). HC Wainwright currently has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($0.84) EPS.

A number of other research firms have also commented on FULC. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Leerink Partnrs lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Stock Up 0.8 %

NASDAQ:FULC opened at $3.03 on Monday. The stock has a fifty day simple moving average of $3.64 and a 200 day simple moving average of $6.44. The firm has a market capitalization of $163.44 million, a price-to-earnings ratio of -9.77 and a beta of 2.24. Fulcrum Therapeutics has a 1-year low of $2.87 and a 1-year high of $13.70.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. National Bank of Canada FI grew its stake in shares of Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after acquiring an additional 4,701 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after purchasing an additional 6,926 shares during the last quarter. Profund Advisors LLC bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at $68,000. Finally, American Century Companies Inc. lifted its stake in shares of Fulcrum Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock valued at $647,000 after purchasing an additional 12,167 shares during the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.